Ervebo

Ervebo is a vaccine designed to prevent Ebola virus disease caused by Zaire ebolavirus. It uses a live, recombinant vesicular stomatitis virus to trigger an immune response. This vaccine is administered intramuscularly and is manufactured by Merck Sharp & Dohme B.V.

Ervebo is used to protect against Ebola virus disease, specifically the Zaire ebolavirus strain. This vaccine is intended for individuals at risk of exposure to the virus, such as healthcare workers and those in outbreak areas. The primary use of Ervebo is to prevent infection and reduce the spread of Ebola.

Common effects of Ervebo may include mild to moderate side effects such as pain at the injection site, fatigue, headache, and muscle pain. These effects are typically temporary and resolve on their own. Severe reactions are rare but can occur, and individuals should seek medical attention if they experience severe symptoms.

Ervebo should be handled with care, following the manufacturer's guidelines for storage and administration. It is important to inform healthcare providers about any allergies or medical conditions before receiving the vaccine. Pregnant women and individuals with weakened immune systems should consult their healthcare provider before use.

Ervebo may interact with other medications or vaccines, particularly those that affect the immune system. It is advisable to discuss all current medications with a healthcare provider before receiving the vaccine. Alcohol and certain supplements may also influence the body's response to the vaccine.